Marcy Nanus - Protalix Biotherapeutics Investor Contact

PLX Stock  USD 1.26  0.01  0.80%   

Executive

Marcy Nanus is Investor Contact of Protalix Biotherapeutics
Address Science Park, Carmiel, Israel, 2161401
Phone972 4 902 8100
Webhttps://www.protalix.com

Protalix Biotherapeutics Management Efficiency

The company has Return on Asset of 0.0933 % which means that on every $100 spent on assets, it made $0.0933 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.725 %, implying that it generated $0.725 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.10 in 2024, whereas Return On Equity is likely to drop 0.24 in 2024. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 6.32 in 2024, whereas Total Assets are likely to drop slightly above 51 M in 2024.
The company has 26.28 M in debt. Protalix Biotherapeutics has a current ratio of 1.3, demonstrating that it may have difficulties to pay its financial commitments when the payables are due. Debt can assist Protalix Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Protalix Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Protalix Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Protalix to invest in growth at high rates of return. When we think about Protalix Biotherapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Katie McDonaldAir Products And
N/A
Matt PettoniAsbury Automotive Group
N/A
Johanna HaggstromLanzaTech Global
45
Roger DewingAir Products And
N/A
Zara SummersLanzaTech Global
N/A
Evgeny AnAir Products And
N/A
Johann ClereLanzaTech Global
N/A
Geoffrey TrukenbrodLanzaTech Global
51
Robert ConradoLanzaTech Global
40
Nilesh KumarLanzaTech Global
N/A
Richard SeidlitzArrow Electronics
45
Jun LiaoAxalta Coating Systems
61
Scott LeprohonGenuine Parts Co
N/A
Jane GrimmNL Industries
52
Carl WolfLanzaTech Global
38
Steven StanleyLanzaTech Global
61
Siddharth ManjeshwarAir Products And
N/A
Franck BaduelGenuine Parts Co
N/A
John HouriganArrow Electronics
N/A
Christopher EvansAxalta Coating Systems
N/A
Tim BowesAxalta Coating Systems
N/A
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people. Protalix Biotherapeutics (PLX) is traded on NYSE MKT Exchange in USA. It is located in Science Park, Carmiel, Israel, 2161401 and employs 208 people. Protalix Biotherapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Protalix Biotherapeutics Leadership Team

Elected by the shareholders, the Protalix Biotherapeutics' board of directors comprises two types of representatives: Protalix Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protalix. The board's role is to monitor Protalix Biotherapeutics' management team and ensure that shareholders' interests are well served. Protalix Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protalix Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roger Kornberg, Independent Director
Eyal MBA, CFO, VP
Yoseph Shaaltiel, Founder and Executive VP of RandD
Shlomo Yanai, Chairman of the Board
Yaron Naos, Senior Vice President - Operations
Amos BarShalev, Independent Director
Tzvi Palash, COO
Yael Fellous, Vice Resources
Dror Bashan, President CEO
Aharon Schwartz, Independent Director
Zeev Bronfeld, Independent Interim Chairman of the Board
Einat Almon, Sr. VP of Product Devel.
Yossi Maimon, CFO, Vice President Treasurer, Secretary
David Granot, Independent Director
Marcy Nanus, Investor Contact
Moshe Manor, CEO and President and Director
Yodfat Buchris, Independent Director

Protalix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protalix Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protalix Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protalix Biotherapeutics' short interest history, or implied volatility extrapolated from Protalix Biotherapeutics options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Protalix Stock analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.39)
Earnings Share
0.09
Revenue Per Share
0.97
Quarterly Revenue Growth
0.217
Return On Assets
0.0933
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.